Research On Sorafenib Inducing Multiple Myeloma U266 Cell Apoptosis And Its Mechanism

Objective: This study aims to investigate the effects of sorafenib on multiple myeloma U266 cells proliferation and apoptosis, and to investigate its mechanism as references for excavating new molecular targeted drugs.Methods: Using MTT test to evaluate the proliferation and inhibition rates of multiple myeloma U266 cells in variable concentrations of sorafenib. Using flow cytometry to assay apoptosis rate of tumor cells. Meanwhile, we designed primers VEGFR-2, VEGFR-3, PDGFR-β, c-Kit and used Q-PCR to assay m RNA expression level of multiple myeloma U266 cells after treatment of sorafenib to confirm the target of sorafenib preliminarily.At last, we adopted western blotting to detect the expression of PDGFR-β and VEGFR-3.Results: It showed diversity on inhibition of proliferation and promotion of apoptosis of multiple myeloma U266 cells due to variable concentrations of sorafenib, and the inhibition rate and apoptosis rate were time-concentration dependent(P﹤0.05). Undergoing the treatments of Sorafenib after 48 h, compared with the control group, m RNA expression of VEGFR-2, VEGFR-3, PDGFR-β, c-Kit down-regulated, especially the VEGFR-3, PDGFR-β. Western blotting showed that expression of VEGFR-3 and PDGFR-β is consistent with Q-PCR results(P﹤0.05).Conclusion: Sorafenib inhibits the proliferation of human multiple myeloma cells and promotes the apoptosis of the tumor cells, the mechanism of which may be that sorafenib can inhibit relevant cell surface receptor activation pathways.